News & Updates

In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.

Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.

Early use of antibiotics among children may lead to several health concerns, including asthma and later infections during childhood years, suggests a study.